Fresh from adding $75 million in venture cash to its accounts, Novato, CA-based Ultragenyx has picked another rare-disease drug candidate, plucking a program from the Baylor Research Institute in Dallas.
Little Novato, CA-based Ultragenyx has gone to a long lineup of backers to add a whopping $75 million in Series B cash only two years after launching.
Ultragenyx Pharmaceuticals has reloaded its coffers after the startup developer of rare disease drugs advanced its lead candidate for hereditary inclusion body myopathy into a Phase II study. According to an SEC filing, the Novato, CA-based biotech has raised a fresh $15.1 million.
An upstart biotech based in Novato, CA and focused on developing new drugs for rare diseases has hauled in an impressive $45 million A round from some high-profile venture backers. TPG Biotech and